Breaking Finance News

CombiMatrix Corp (NASDAQ:CBMX) target price raised to $5.40, reported today by Aegis

CombiMatrix Corp (NASDAQ:CBMX) had its price target upped to $5.40 by Aegis in an issued report announced 10/6/2016. The upped price target suggests a potential upside of 0.73% from the company's most recent close.

Having a price of $3.12, CombiMatrix Corp (NASDAQ:CBMX) traded -1.57% lower on the day. With the last stock price close down -2.56% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. CBMX has recorded a 50-day moving average of $3.03 and a 200-day moving average of $3.22. 38,713 shares of the stock were exchanged, down from an average trading volume of 229,348

Performance Chart

CombiMatrix Corp (NASDAQ:CBMX)

With a total market value of $0, CombiMatrix Corp has 52 week low of $2.62 and a 52 week high of $18.15 .

About CombiMatrix Corp (NASDAQ:CBMX)

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *